Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 17/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952282 | 0.85 | AOC3 (0.41) | MGLLAOC3ABHD6 | |
| SCHEMBL3947105 | 0.81 | PPARG (0.38) | — | |
| SCHEMBL3950853 | 0.78 | PRMT6 (0.45) | — | |
| SCHEMBL6032489 | 0.78 | HSD17B1 (0.57) | MGLLAOC3ABHD6 | |
| SCHEMBL5394147 | 0.77 | AOC3 (0.47) | MGLLAOC3ABHD6 | |
| SCHEMBL14558989 | 0.75 | GLS (0.45) | MGLL | |
| SCHEMBL14558959 | 0.75 | GLS (0.46) | MGLL | |
| SCHEMBL6254244 | 0.75 | AOC3 (0.50) | MGLLAOC3ABHD6 | |
| SCHEMBL6473330 | 0.74 | HSD17B2 (0.54) | AOC3 | |
| SCHEMBL5383620 | 0.74 | HSD17B2 (0.56) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582663-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2008-03-20 | — | — | US | disclosed |
| US-7285568-B2 | Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-23 | — | — | US | disclosed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | MGLL 124/4885AOC3 2202/4885ABHD6 222/4885 |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | MGLL 192/4885AOC3 2177/4885ABHD6 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.